Exogeneous cholic acid is known to be absorbed from the small intestine and then maintained within the enterohepatic circulation. A noble compound, CA 102(a conjugate of cholic acid which could be a carrier of anticancer agents with an alkylating agent, bis-(chloroethyl)glycine was synthesized. The antitumor activity of CA 102 was characterized
in vitro and
in vivo using intraportal, s. c. and i. p. implanted colon 26 and other experimental ascitic tumors including S 180, Ehrlich, P 388, M 5076. It was shown that CA 102 itself had alkylating and cytocidal activity by reaction with 4-(4-nitrobenzyl) pyridine and by growth inhibition of cultured L 1210 cells, respectively. Intraperitoneal administration of CA 102 showed strong antitumor activity in experimental ascitic tumors. And CA 102 had strong antitumor activity by p. o. administration in intraportal implanted colon 26 but had no activity in s. c. and i. p. implanted colon 26. Acute toxicity of CA 102 was examined in mice. The high value of LD
50 (more than 2, 000 mg/kg(p. o.))comparing with other antitumor drugs with direct alkylating and cytocidal activities such as nitrogen mustard (1.1 mg/kg (p. o., rat)) or carboquone (5, 43 mg/kg (i. p., mouse)) was observed. These studies strongly suggest that the localized distribution of CA 102 within the enterohepatic circulation reduced the systemic toxicity and increased the selective cytotoxicity against tumor cells in the liver.
View full abstract